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Abstract
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the 
gastrointestinal tract. The stomach is considered the most common site of GIST, and the 
most common histopathological type of GISTs is spindle cell. Mutational analysis may 
help in defining the management of GIST. Multiple stratification modules are available 
for the estimation of GISTs’ prognosis. Surgery is considered the only curative option for 
GISTs. The discovery of KIT protein has allowed better identification of GISTs and has 
allowed creation of selective tyrosine kinase inhibitors which dramatically affected GIST 
management. Results of trials on neoadjuvant imatinib therapy are promising. Adjuvant 
imatinib therapy is recommended for 3 years and has proven to improve outcome in 
high-risk GISTs. New therapeutic agents are now available in case of imatinib resistance. 
Follow-up of patients with GISTs depends on the type of GIST.
Keywords: GIST, gastric GIST, imatinib, tyrosine kinase inhibitors, primary GIST, 
metastatic GIST, recurrent GIST, imatinib resistance, KIT, PDGFRA
1. Introduction
Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastro-
intestinal tract (GIT) [1, 2]. All GISTs are considered to have some degree of malignant potential 
[3]. The most common site of GISTs is the stomach (60%) [4]. Other common sites are jejunum 
and ileum (30%), duodenum (5%), rectum (2–3%), colon (1–2%), and esophagus (<1%) [4].
It has been estimated that GISTs comprise about 18% of all sarcomas and 80% of mesen-
chymal tumors found in the GIT [5]. GIST’s true incidence has been underestimated as they 
were usually misdiagnosed as leiomyomas, leiomyosarcomas, and leiomyoblastomas [6]. 
A study which used the Surveillance, Epidemiology and End Results (SEER) data from the 
National Cancer Institute, reported that the incidence of GIST has increased from 0.028 cases 
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per 100,000 in 1992 to 0.688 cases per 100,000 in 2002, which is a 25-fold increase in incidence. 
This increase occurred after the availability of diagnostic criteria, especially after the year 2000 
[7]. In 1992, 93% of mesenchymal tumors of GIT were identified as smooth muscle neoplasm 
and 6% as GISTs. In 1995, Miettinen et al. [8] discovered that 70% of GIST are positive for 
CD34, a myeloid progenitor cell antigen. Furthermore, CD34 were also found in Schwann 
cell tumors and some smooth muscle tumors [6]. In the late 1990s, Hirota et al. [9] discovered 
that GIST expresses KIT (CD117), a receptor tyrosine kinase encoded by the proto-oncogene 
c-kit. Subsequent studies showed that mutations in c-KIT are present in 85–100% of GIST 
cases, but not in leiomyomas or leiomyosarcomas. These findings made a breakthrough in 
identifications and management of GISTs. In the SEER data published by Perez et al. [7], 82% 
of mesenchymal tumors of GIST were classified as GIST and 17% were classified as smooth 
muscle neoplasms in 2002, which shows how GISTs were poorly identified and were under-
diagnosed [7]. GISTs appear to be more common in African Americans, Asians, and Pacific 
Islanders than in Caucasian patients, and men appear to have a slightly increased incidence 
[7, 10]. GISTs tend to be infrequent before the age of 30 and are most common after the age of 
60 [7]. The median age of diagnosis is between 58 and 65 years [7, 10–13]. Two studies from 
Europe have shown that GIST incidence is about 1.1 cases/100,000/year [11, 14].
Though rare, GISTs can also affect the pediatric population. A study carried out by Miettinen 
et al. which included 1782 patients with gastric GIST, reported 44 cases under the age of 21 
(2.6%) [15] with an age range from 5 to 21 and a median age of 14.5 years [15]. Prakash et al. 
[16] reported six cases of gastric GIST with a mean age of 12.8 and an age range from 10 to 18. 
Pediatric GISTs are commonly of epithelioid type, occur more in females, and have a higher 
incidence of multifocal presentation and lymph node metastasis. Pediatric GISTs also tend to 
lack a KIT or a platelet-derived growth factor receptor-α (PDGFRA) mutation [17, 18].
2. Risk factors
There are no known risk factors for GIST. Though most of GISTs are sporadic, the minority 
occur as part of hereditary syndrome.
Familial GIST syndrome: several family members with hereditary mutations in either the KIR 
or PDGFRA genes have been reported in the study [19–28]. These families have a higher risk 
to develop multiple gastric and small bowel GISTs. Some patients may have skin hyperpig-
mentation, dysphagia, gastrointestinal autonomic nerve tumors, intestinal fibromatosis, and 
inflammatory fibroid polyps [19–28].
Carney-Stratakis syndrome is an autosomal-dominant disease which is characterized by dyad 
of multifocal GISTs and paragangliomas [29]. Patients do not have KIT or PDGFRA muta-
tions, but do have mutations of succinate dehydrogenase subunits (SDH) A, B, C, or D [30].
Carney’s triad: a very rare non-heritable syndrome characterized by gastric GIST, paragan-
glioma and pulmonary chondromas. These patients are characterized by mutations succinate 
dehydrogenase subunit (SDH) C [29] but lack mutations of KIT and PDGFRA.
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Neurofibromatosis type 1: patients with NF1 are more predisposed for multifocal GISTs that 
mainly affect the small intestine [31].
3. Molecular biology
GISTs are characterized by mutations in KIT and PDGFRA genes that encode tyrosine kinase 
receptor type III [32].
3.1. KIT-mutant GIST
Though 95% of GISTs are positive for KIT, only 60–85% have mutations in KIT. The most 
common mutations encountered are mutations of exon 11 (juxtamembrane domain) [4] which 
is found in about two-thirds of GISTs. Exon 9 (extracellular domain) is less common (9–20%) 
and is principally correlated with GIST of the small bowel and has a greater malignant poten-
tial [4, 33].
3.2. PDGFRA-mutant GIST
About 5–10% of GISTs have PDGFRA mutations which have a tendency for localized gastric 
GIST and epithelioid type [4]. The most common type of mutation is the PDGFRA exon 18 
mutation D842V, which is associated with imatinib resistance and has a lower risk of recur-
rence than GIST with KIT mutations as well as a more benign course 9 [34].
3.3. Wild-type GIST
Approximately 12–15% of adult GIST and 90% of pediatric GIST do not have KIT and PDGFRA 
mutations [33]. Wild-type (WT) GISTs comprise GISTs that arise in NF1, Carney-Stratakis 
syndrome, and Carney triad [4]. WT GISTs may have other forms of mutations. BRAF V600E 
substitution has been described in 7–13% of WT GISTs [35, 36]. About 30% of WT GISTs are 
SDH deficient and occur solely in the stomach. They mainly affect children and young adults 
and have a variation in their nature from being indolent to progressive [4].
4. Histopathology
The three main histopathologic subtypes of GIST are spindle cell, epithelioid, and mixed types, 
with spindle cell type being the most common constituting about 70% of GISTs, while the other two 
subtypes, epithelioid and mixed, are less common, accounting for 20 and 10% of all GISTS, respec-
tively [6]. Epithelioid GIST is commonly observed in the stomach and omentum [6]. About 95% of 
GIST will be immunohistochemical positive for CD117(c-KIT) [4]. Epithelioid type has a weaker 
KIT positivity than spindle cell type [37]. In addition, 70–90% are positive for CD34, 20–30% for 
actin, 8–10% for S-100, and 2–4% for desmin [38]. DOG1 marker, also known as ANO1, has more 
than 95% sensitivity for GIST and is expressed in more than 35% of GISTs negative for c-kit [39, 40].
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5. Clinical picture
About 60% of GISTs occur in the stomach, 30% in the jejunum and ileum, 5% in the duo-
denum, 2–3% in the rectum, 1–2% in the colon, and < 1% in the esophagus [4]. About 70% 
of GISTs are symptomatic, 20% are asymptomatic, and 10% are discovered at autopsy [41]. 
The main symptoms of GIST are GI bleeding, abdominal discomfort, and abdominal mass. 
GISTs are highly vascular tumors and may grow quickly and cause massive gastrointestinal 
or intraperitoneal hemorrhage [42]. Obstruction symptoms such as dysphagia, obstructive 
jaundice, and small bowel obstruction may also occur [42].
Extragastrointestinal GISTs occur in less than 10% of GISTs and mainly occur intra-abdomi-
nally and affect omentum and mesentery. Such tumors are considered more aggressive than 
gastric GIST and have a poorer prognosis similar to small bowel GISTs [43, 44].
About 50% of patients will present with metastatic disease with the most common site of metas-
tasis being liver at about 65%. Other common metastatic sites are omentum and peritoneum. 
Extra-abdominal metastasis, lung bone, and lymph node metastasis are not common [13].
6. Prognosis
Various risk stratification models (Table 1) have been proposed that are based on site, size, 
mitotic index, and tumor rupture. Gastric GISTs are known to have better prognosis than 
non-gastric GIST [46].
Tumor rupture is known to be associated with a very high risk of GIST recurrence [47]. TNM 
staging is also available for GIST staging [48]. However, these stratification systems are not 
commonly used in clinical practice.
As an alternative to the risk classification systems that stratify patients into distinct groups, 
others have quantified the risk of disease recurrence after complete resection as a continuous 
variable through the use of a GIST nomogram that includes the disease site [49]. Different 
nomograms have been developed by others as well.
GIST nomograms [49, 50] have been used to assess the risk of disease recurrence after com-
plete resection as a continuous variable instead of the risk stratification systems that stratify 
patients into separate groups. Recently, a new risk stratification system has been developed 
in which tumor size and mitotic counts were assessed as continuous, nonlinear variables, and 
prognostic contour maps were then generated based upon these data plus site and tumor 
rupture [51]. These prognostic contour maps resulting from nonlinear modeling are used for 
the assessment of individualized outcomes.
Deletion type of mutations affecting codons 557 and 558 in KIT gene is considered a risk factor 
for recurrence regardless of different classification systems [4].
Pfetin is a prognostic biomarker which is still under investigation with promising results. Lack 
of Pfetin expression seems to be associated with a higher GIST recurrence [52]. Orita et al. [52] 
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had 45 GIST cases, of which 37 were in the stomach. All GIST patients had R0 resection. There 
were seven recurrences with five recurrences being gastric GIST recurrences. Thirteen GIST 
patients were Pfetin negative and 5/13 Pfetin negative GISTs had recurrences [52].
7. Diagnostic evaluation
A computed tomography (CT) scan (Figure 1a and b) is considered the first imaging to be done 
to evaluate anatomic location, extension, and metastasis of GISTs. Oral and IV contrast should 
be given to delineate bowel margins. GISTs can display endophytic and exophytic growth, 
and large GISTs may appear heterogeneous due to focal areas of hemorrhage or necrosis [53]. 
Magnetic resonance imaging (MRI) is used to further evaluate liver metastasis or rectal GIST 
[54]. Fluorodeoxyglucose-positron emission tomography (FDG-PET) is highly sensitive but not 
specific for GIST, and it is mainly useful to monitor response to tyrosine kinase inhibitors [55, 56].
Upper GI endoscopy may be useful for gastric GIST. Both GISTs and leiomyomas will appear 
as a submucosal mass with normal overlying mucosa and bulging into gastric lumen. Mucosal 
ulceration may occur. Endoscopic ultrasound (Figure 2) may not be useful, however, when 
combined with FNA sensitivity, and accuracy may reach 82 and 86%, respectively [57]. Routine 
biopsy is not needed routinely for local resectable gastric GISTs proved by imaging studies.
Classification 
system
Prognostic 
criteria
Risk definition Risk groups Comments
NIH [6] Tumor size
Mitotic index
Aggressive 
behaviors of 
GISTs
Very low risk
Low risk
Intermediate risk
High risk
Does not differentiate between 
malignant and benign tumors knowing 
the fact that even small-size tumors with 
a low mitotic count may metastasize
Does not take GIST site into 
consideration
Modified NIH 
[45]
Tumor size
Mitotic index
Primary 
tumor site
Tumor 
rupture
Risk of recurrence Very low risk
Low risk
Intermediate risk
High risk
Tumor location outside the stomach 
is a prognostic factor for survival 
independent of the mitotic count and 
tumor size
AFIP [46] Tumor size
Mitotic index
location
Risk of recurrence Very low risk
Low risk
Intermediate risk
High risk
This classification considered a total area 
of 5 mm2 in 50 fields
HPF characterized by the use of different 
optical components, while in practice, 50 
HPF typically corresponds to a total area 
of 10 mm2
This classification is recommended by 
GEIS guidelines
Table 1. Different stratification systems for GISTs.
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8. Management
Complete surgical resection is the recommendation of choice for localized GIST with a 
target of R0 resection with complete surgical removal of the tumor without disturbing the 
capsule [4]. Though surgery is considered the only curative option for GISTs, a multidisci-
plinary approach is needed for best medical and surgical management. Segmental resection 
of the stomach as wedge resection is accepted, and extensive resection is usually not needed. 
Lymphadenectomy is also not required as GISTs rarely metastasize to lymph nodes [4]. The 
discovery of KIT(CD117) (receptor tyrosine kinase) in GISTs has revolutionized GISTs man-
agement. Imatinib mesylate is a selective tyrosine kinase inhibitor that selectively inhibits KIT 
and had a significant impact on the prognosis of GISTs as will be discussed subsequently.
Figure 1. An axial ( A) and coronal (B) CT image showing a well-defined mass lesion ( arrow) in the anterior gastric wall in 
the proximal stomach  measuring 2.9x2.5x2.7.
Figure 2. Gastric EUS showing a well-defined hypoechoic  gastric submucosal lesion (between the two 
arrows) from the fourth layer  of the stomach wall suggestive of GIST.
Gastric Cancer - An Update74
8.1. Management of primary resectable disease
8.1.1. Preoperative therapy for primary GISTs
There is still no consensus on the role of neoadjuvant imatinib therapy in resectable GISTs [4]. 
However, imatinib therapy might be considered for advanced or borderline resectable tumors. 
Multiple prospective and randomized trials have shown that neoadjuvant imatinib therapy (with 
a dose of 400 mg/day) in cases of advanced GIST will cause a reduction in tumor size and enable 
an R0 resection with an increased chance of organ preservation (Table 2). However, if KIT exon 
9 mutation is detected and neoadjuvant therapy is planned, the dose may be increased to 800 mg 
per day as recommended by the European Society for Medical Oncology (ESMO) guidelines.
Study Published 
year
Type of 
study
Type of 
patients 
assessed
Dose of 
imatinib 
given
Median 
follow-up
Primary 
end 
point
Results
RTOG 
(Radiation 
Therapy 
Oncology 
Group) 
0132 [1, 
116]
2009 Phase II 
prospective
1. Advanced 
primary GIST 
of >5 cm 
(Group A, 
30 p)
2. Recurrent 
or metastatic 
tumors of 
≥2 cm (group 
B, 22 p)
Neoadjuvant 
600 mg/
day for 
8–12 weeks 
of treatment 
with a 
median of 
65 days then 
600 mg/day 
adjuvant 
therapy for 
2 years
1. Group 
A 4.9 y
2. Group 
B 5.5 y
RFS 1. The 2-y estimated 
overall survival was 
93.3 and 90.9% in 
Group A and Group 
B, respectively, with a 
median follow-up of 3 y
2. The 5-y PFS and OS 
were 57% in group 
A, 30% in group B, 
and 77% in group 
A, 68% in group B, 
respectively
McAufliffe 
et al. [117]
2009 Phase II 
randomized
Primary GIST
Metastatic 
GIST of 
≥1 cm
3. 19 patients 
involved
Neoadjuvant 
600 mg/day 
given at 3, 
5, or 7 days; 
then adjuvant 
600 mg/day 
for 2 years
32 m Tumor 
cell 
apoptosis
All patients had a 
radiographic response 
with 1 week of 
imatinib therapy. In 
addition, the rate of 
tumor cell apoptosis 
had a positive 
correlation duration 
of imatinib therapy 
where the maximum 
tumor cell apoptosis 
was seen with 7 days 
neoadjuvant imatinib 
therapy
APOLLON 
[118]
2012 Prospective 
open-label 
phase II
1. KIT or 
PDFRA 
positive 
GIST. Tumors 
had to be 
locally 
advanced, 
potentially 
resectable, 
and no 
metastasis
2. 45 patients 
involved
Neoadjuvant 
for 6 months 
400 mg/
day with no 
postoperative 
adjuvant 
therapy
36 m Overall 
tumor 
response
1. R0 resection was 
achieved in 30/34 
patients and PFS at 
3 years was 85.2%. 2. 
Predicted operation 
was downsized with 
imatinib therapy
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8.1.2. Surgery for primary GISTs
Surgical resection with negative margins is the recommended treatment for localized primary 
GISTs and is the only curative treatment for GIST [58, 59]. A published study that contained 
200 GIST patients [13] with 46.5% of the cases being primary local GISTs and 39% of the 
cases gastric GIST, which was the most common type, reported that complete resection was 
achieved in 80 patients (86%) with primary disease, and those patients had a 54% of a 5-year 
survival rate with a median survival of 66 months, while patients with incompletely resected 
or unresectable disease had a median survival of 22 months. Complete resection of even a 
locally advanced disease is associated with improved survival [60].
Surgical resection is recommended for GISTs with a size of 2 cm or more [61]. However, there 
is still no consensus on the management of GIST less than 2 cm [62, 63]. Multiple studies have 
reported the occurrence of microscopic gastric GIST [64–67]. Agaimy et al. [68] discovered 
microscopic GISTs in 22.5% of consecutive autopsies for adults of >50 years old with all lesions 
detected in cardia, fundus, and proximal body. Kawanowa et al. [67] reported 35% of micro-
scopic GISTs in patients who had gastric resection for stomach cancer. Ninety percent of these 
microscopic GISTs were in the upper body.
GISTs have been reported as an incidental finding discovered by routine OGDs and in gastric 
specimens post sleeve gastrectomy [69, 70] and have caused a dilemma about whether routine 
preoperative gastroscopy should be done before each bariatric procedure to avoid missing 
such incidental tumors [70]. Sepe et al. [71] had developed an algorithmic approach for gastric 
GIST which was adopted by The National Comprehensive Cancer Network (NCCN). They 
proposed that GISTs with no high-risk EUS features (irregular border, cystic spaces, ulcer-
ation, echogenic foci, and heterogeneity) can be followed up by EUS. NCCN adopted this 
approach and suggested that EUS surveillance every 6–12 months may be done for GISTs of 
<2 cm with no high-risk features [72].
Study Published 
year
Type of 
study
Type of 
patients 
assessed
Dose of 
imatinib 
given
Median 
follow-up
Primary 
end 
point
Results
Kurokawa 
et al. [59]
2017 Phase II 
prospective
1. Primary 
GISTs in the 
stomach with 
tumor size of 
≥10 cm with 
no metastasis
2. 53 patients 
enrolled
1. 
Neoadjuvant
400 mg/day 
for 6 months
2. Adjuvant 
400 mg/day
for at least 
1 year
32 m R0 
resection 
rate
1. The R0 resection 
was achieved in 91% 
of patients (48/53) 
and at least half of the 
stomach was spared 
in 42/48 patients who 
had R0 resection.
2. After R0 resection, 
all patients received 
imatinib 400 mg/day 
for at least 1 year. 
The 2-year OS and 
PFS were 98 and 89%, 
respectively
RFS, recurrence-free survival; OS, overall survival; y, years; m, months.
Table 2. Summary of studies assessing the role of neoadjuvant imatinib in treatment of GIST.
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Endoscopic resection of gastric small submucosal tumors is a promising technique with a favor-
able outcome. Andalib et al. [73] described endoscopic resection of 12 cases with gastric GISTs 
arising from muscularis propria with an average size of 2.4 cm and no complications of bleeding 
or perforation. However, 50% of cases had positive microscopic margins but there is no evidence 
that a positive microscopic margin after macroscopic resection requires re-excision [74], and with 
an average follow-up of 12 months, none of the patients had recurrence. Zhou et al. [75] described 
endoscopic resection of 26 cases of gastric submucosal tumors, out of which 16 were gastric GISTs. 
The mean tumor size was 2.8 cm and all of the tumors were resected completely without interrup-
tion of capsule. None of the patients had severe complications as bleeding perforation or abdomi-
nal abscess [75]. No recurrence was found with a mean follow-up of 8 months. Nevertheless, tumor 
spillage and perforation after endoscopic resection had been described [76], and the technique 
needs to be validated by prospective multicenter trials and cannot be routinely recommended.
As mentioned before, surgery is the main and only curative option for primary localized 
resectable GISTs [77]. The primary technical goal of surgery is complete macroscopic resec-
tion with an intact pseudocapsule and a negative microscopic margin (R0 resection) [77]. 
Routine lymphadenectomy is not needed as adult GISTs rarely metastasize to lymph nodes 
[78]. Pediatric GISTs, however, have a higher incidence of lymph node metastasis [78] and 
lymphadenectomy may be needed for this population [79, 80].
Wedge resection with negative margins is the usual treatment for gastric GISTs [81] unless the 
tumor is found invading the surrounding tissues where en bloc resection of involved surrounding 
organs may be appropriate [81]. Patients with low-grade tumors may have a 5-year survival up to 
80%. It is still important to avoid tumor rupture and spillage, as this is associated with an increased 
risk of recurrence and low survival rates [47, 60]. The role of laparoscopy in gastric GISTs is devel-
oping with promising outcomes. Two meta-analysis studies have concluded that, when compared 
to open, laparoscopy seems to result in shorter hospital stays with no difference in operative time, 
adverse events, estimated blood loss, margin positivity, or overall survival (OS) and recurrence 
rates [82, 83]. Current NCCN guidelines [84] recommend that a laparoscopic wedge resection for 
gastric GISTs of 5 cm or less is appropriate and tumor resection may be done using a laparoscopic 
or a laparoscopic-assisted technique with hand port for GISTs more than 5 cm.
8.1.3. Adjuvant therapy for primary GISTs
Unlike neoadjuvant imatinib therapy, the role of adjuvant imatinib therapy is better estab-
lished. Recurrence rates of 50% have been reported in localized GISTs that have been com-
pletely resected [4]. Multiple randomized trials have proven the efficacy of adjuvant imatinib.
The first randomized phase II trial done on the role of adjuvant imatinib was The American 
College of Surgeons Oncology Group (ACOSOG) trial Z9000 [85] which assessed the role 
of adjuvant imatinib dose of 400 mg/day for 1 year for patients with a high-risk GIST. High 
risk was defined in this study as a tumor diameter of >10 cm, intraperitoneal tumor rupture, 
or up to four peritoneal implants. The study involved 106 patients with GISTs, 50% of the 
cases were gastric GISTs. After a median follow-up of 7.7 years, the 1-, 3-, and 5-year overall 
survivals (OS) were 99, 97, and 83%, respectively, which is much better than historical controls 
(35%) [85]. The 1-, 3-, and 5-year RFS rates were 96, 60, and 40%, respectively. Recurrence free 
survival (RFS) was lower with a larger tumor size, KIT exon 9 mutation, a high mitotic rate, 
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and older age. They concluded that adjuvant imatinib for 1 year prolongs RFS and OS, but the 
optimal duration of adjuvant imatinib was still to be decided.
Three phase III trials have assessed the efficacy of adjuvant imatinib, ACOSOG Z9001 [86], SSG 
XVIII trials [87], and EORTC 62024 [88]. Only ACOSOG Z9001and EORTC 62024 had no treat-
ment control arm. The American College of Surgeons Oncology Group (ACOSOG) trial Z9001 
[86] is the first randomized phase III, double-blinded, placebo-controlled, multicenter trial done 
regarding the role of adjuvant imatinib therapy. A total of 359 patients were randomized to 
receive imatinib 400 mg/day for 1 year, and 354 patients were randomized to receive placebo 
for 1 year following surgical resection of the tumor. The trial reported that imatinib therapy 
significantly prolonged RFS when compared to placebo (98 versus 83%) in all risk categories 
(based upon size, mitotic rate, and location in the GI tract) [86]. Overall survival was similar at 
1 year with 99.2 versus 99.7%, and imatinib therapy was tolerated with low side effects. The trial 
planned a minimum follow-up of 3 years for the patients but it was stopped early with a shorter 
median follow-up of 19.7 months. The lack of difference in overall survival in this trial may be 
explained by a short duration follow-up, a limited number of relapses, and a high degree of 
efficacy of imatinib in relapsed disease [89]. As a result of this study, The U.S. Food and Drug 
Administration approved adjuvant imatinib in the adjuvant setting by the U.S. Food and Drug 
Administration for GISTs of ≥3 cm, without guidance as to the optimal duration of treatment 
or which patients are most likely to benefit. The long-term results of this study were published 
with a median follow-up of 74 months with no difference in the 5-year RFS and OS.
Another phase III prospective, randomized, open-label trial was done by The Scandinavian 
Sarcoma Group (SSG) XVIII [87]. This trial compared 36 versus 12 months therapy of adjuvant 
imatinib (400 mg daily) in 400 patients with a high-risk-resected GIST with a median follow-
up of 54 months. A high-risk GIST was defined as a tumor size of >10 cm, a mitotic count 
of >10/50 high-power fields (HPF), a tumor size of >5 cm with a mitotic rate of >5/HPF, or a 
tumor rupture. About 50% of the patients had gastric GIST in this study. The study reported 
prolonged 5-year RFS and OS rates for patients assigned for 36 months imatinib adjuvant 
therapy compared with patients assigned for the 12-month group, 65.6 versus 47.9% and 92% 
versus 81.7%, respectively. The results of this trial resulted in NCCN guidelines recommend-
ing adjuvant imatinib for at least 3 years for patients with intermediate or high risk of GIST 
recurrence [90]. In a latter follow-up report for the Scandinavian trial with a median follow-up 
of 90 months, patients assigned to a 3-year group had a persistent favorable outcome with 
significantly greater RFS (71 versus 52% and overall survival (92 versus 85%) [91].
The EORTC 62024 trial [88] is a phase III open-label randomized trial which assessed the effi-
cacy of adjuvant imatinib for 2 years in localized surgically resected high- or intermediate-risk 
GISTs [88]. After surgical resection, 908 patients were randomized to either receive 2 years 
of imatinib 400 mg/day or observation alone. After a median follow-up of 4.7 years, RFS at 
3 years was 84% in imatinib group versus 66% in control group and 69 versus 63% at 5 years 
(P < 0.001). No difference was detected in a 5-year OS. The 5-year imatinib failure-free survival 
(IFFS, the time to death or starting a TKI other than imatinib) was 87% in imatinib group and 
84% in control group (P = 0.23). Among patients with a high-risk GIST (528 patients), there 
was a trend favoring adjuvant imatinib (P = 0.087).
As a result of the findings of the previous trials, both NCCN and ESMO guidelines as well as 
consensus of the scientific community recommend 3 years of adjuvant treatment with imatinib 
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in high-risk patients [4]. By contrast, adjuvant therapy is not needed in low-risk patients, and 
there are no sufficient data to support adjuvant imatinib therapy in intermediate-risk patients 
[4]. Whether doses higher than 400 mg/day should be used is still questionable. Moreover, 
whether the imatinib dose should be continued more than 3 years is not known. A single-arm 
phase II 5-year adjuvant imatinib trial, PERSIST5, has completed its accrual, and still sur-
vival data reports are pending. Whether patients who had R1 resection for their GISTs should 
receive adjuvant imatinib is also not clear as there are no data to support adjuvant imatinib 
therapy in such cases. Re-excision may be appropriate in these situations.
8.2. Management of metastatic and recurrent GIST
GISTs mostly recur in the first 5 years after surgical resection, while less recurrence is observed 
after 10 years [92]. A study, with pooled analysis from 10 series and included 1625 patients, 
reported that 5-year, 10-year, and 15-year RFS were 70.5, 62.9, and 59.9%, respectively [92]. It 
was observed that the larger the size of the tumor, the higher the risk of recurrence. Compared 
with tumors of <1.1 cm in size, tumors with sizes of 1.1–2, 2.1–5, 5.1–10.0, 10.1–15.0, and > 15 cm 
were associated with a hazard ratio (HR) of 2.19, 4.45, 21.56, and 27.98, respectively. There was 
also a positive correlation between tumor mitosis rates and risk of recurrence. Compared with 
tumors with a very low mitosis count (<2/50 HPF), tumors with a low count (2–5/50 HPF), a 
moderate count (6–10/50 HPF), and a high count (>10/50 HPF) were associated with HR of 
3.78, 11.1, and 22.09, respectively. Gastric GISTs had better RFS than other types of GISTs. 
Tumor rupture was associated with a worse prognosis. About two-third and half of patients 
with recurrence had liver metastasis and peritoneal disease, respectively [93].
Patients with advanced (primary unresectable or metastatic GIST) are treated initially with 
imatinib rather than surgery.
A phase III randomized trail (EU-AUS trial) [94] included 946 patients randomized to either 
receive imatinib once or twice daily. At a median follow-up of 760 days, the trial reported that 
56% of 473 patients receiving imatinib 400 mg/day had progressed while 50% (235) of 473 
patients assigned to imatinib 400 twice/day had progressed. OS was 69 and 74%, respectively. 
There was no significant difference in response rates between the two groups. The study con-
cluded that, although a daily dose of 400 mg of imatinib is enough, a dose of 400 mg twice 
daily significantly prolongs PFS.
In a phase II open-label multicentric randomized trial, B2222 study, which included 147 patients 
with advanced GIST, 73 patients received imatinib 400 mg/day and 74 patients received ima-
tinib 600 mg/day. The study reported equal response rates, median progression-free survival, 
and median overall survival among both groups with a median survival of 57 months for 
all patients. No advantage was seen with using a higher dose of imatinib (600 mg/day) in 
this study. This study was followed by another phase III open-label multicentric randomized 
trial, S0033 study [95], which compared imatinib dose 400 mg/day to imatinib dose 400/mg 
twice daily. The study included 746 patients with advanced GIST with a median follow-up of 
4.5 years. Similar findings were found with no statistically significant difference in response 
rates, PFS, or OS between either doses of imatinib. However, after progression on imatinib 
dose of 400 mg/day, 33% of the patients who were crossed over to receive a higher imatinib 
dose 400 mg twice daily achieved either an objective response or a stable disease [95].
Gastric GIST
http://dx.doi.org/10.5772/intechopen.77297
79
Further analysis of data from EU-AUS and S0033 trials reported that tumor genotype has 
a significant prognostic impact on PFS and OS, with tumors with mutation of KIT exon 9 
having a worse prognosis when compared to tumors with mutation of KIT exon 11 [96, 97].
A subsequent meta-analysis combining S0033 and EU-AUS trials [98] reported a minor albeit 
significant PFS advantage for a higher imatinib dose of 400 mg twice daily for patients with 
advanced GIST. The PFS benefit was only evident in patients with KIT exon 9 mutations 
treated with a high-dose imatinib without difference in OS between the two groups, while 
patients with KIT exon 11 had a more favorable prognosis. Thus, genotype is required for the 
treatment of advanced or metastatic GISTs.
The findings of the results of the previous studies [94, 95, 98] designated imatinib dosage of 400 mg/
day to be the standard treatment for patients with advanced GISTs, and patients with advanced 
GISTs with KIT exon 9 mutations to be started on the higher imatinib dose (400 mg twice daily), 
keeping in mind that the toxicity of imatinib is dose-dependent [99]. Imatinib treatment should 
be life long as interruption of treatment has a higher rate of disease progression as proven by the 
phase III randomized trial [100–102]. Indications of surgery in advanced GISTs are still debatable. 
Multiple retrospective studies have shown that debulking surgery may be beneficial in patients 
with a stable disease without generalized progression as surgery may improve the prognosis. 
However, patients should be treated with imatinib first before attempting surgery [103–108].
8.3. Alternatives of imatinib in case of resistance or progression of disease with 
imatinib therapy
Most patients with advanced GISTs will show improvement with imatinib therapy, although 
a subgroup of patients will fail to show a response. Resistance to imatinib may be primary or 
secondary. Primary resistance is defined as continuous growth or growth within 6 months of 
therapy, and occurs in 15–20% of patients with advanced GIST [109] and occurs frequently in 
patients with wild-type (WT) GIST or KIT exon 9 mutations or D842V mutation in PDGFRA 
exon 18 [110]. Unfortunately, most patients develop secondary resistance, which is defined 
as patients who received treatment with imatinib for longer than 6 months and had an initial 
response and then developed progressive disease. Secondary KIT mutations occur frequently 
in KIT exons 13, 14, and 17 and a D842V mutation in PDGFRA exon 18 [111–113].
If a patient develops resistance, escalating imatinib dosage to 800 mg daily or shifting to a 
second-line therapy like sunitinib may be recommended.
Sunitinib is considered a second-line therapy for patients with advanced GIST refractory to 
imatinib therapy. Outcomes of a randomized phase III trial versus placebo reported a prolon-
gation of the time to progression from 1.5 to 6.3 months in patients with GIST who progressed 
on imatinib treatment [114]. It is approved by the EMA and the FDA for the treatment of 
patients with GIST resistant to imatinib therapy and for patients who are not tolerant to ima-
tinib therapy.
In case of progression on imatinib and sunitinib, regorafenib is considered a third-line 
therapy [4]. It was recently approved by EMA and FDA for the treatment of patients with 
unresectable or metastatic GISTs who are resistant or intolerant to imatinib and sunitinib, and 
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it was tested in a phase III randomized trial which included patients with advanced GIST who 
progressed after imatinib and sunitinib failed. The study reported that regorafenib, when 
compared to placebo, has significant improvement in PFS [115]. Inadequate data are available 
for the efficacy of other tyrosine kinase inhibitors (e.g., sorafenib, pazopanib, and ponatinib) 
for imatinib and sunitinib refractory GISTs [4].
9. Follow-up
There are no studies assessing the efficacy of different follow-up modules. Nevertheless, 
follow-up strategies were created based on the fact that most recurrences occur within the 
first 5 years after surgery.
A follow-up schedule frequency is based on the risk of aggressiveness and recurrence of 
GISTs [4]. CT is favored over other imagings, such as MRI and FDG-PET scan, because it is 
more readily obtainable, although other modalities can be used in case CT is inconclusive.
9.1. Follow-up for localized resectable GISTs
Very low-risk patients with surgically removed tumor do not require a follow-up. Low-risk 
patients require an annual CT. Intermediate- and high-risk patients require CT every 4 months 
for the first 1–2 years, every 6 months for 3–5 years, and then CT every year thereafter [4].
9.2. Follow-up for unresectable/metastatic GISTs
Follow-up should be done at the start of every 3 months and can be delayed to every 6 months 
if there is response to the treatment.
10. Conclusion
Surgery is the only curative option for GISTs. The discovery of KIT protein had allowed the 
development of tyrosine kinase inhibitors which considerably affected the diagnosis and 
management of GISTs. A multidisciplinary approach is required for optimal management. 
Neoadjuvant imatinib therapy has produced favorable results so far; however, more studies 
are needed to define the optimal dose and duration of imatinib therapy. Adjuvant imatinib 
therapy for 3 years improves outcome in patients with high risk. Mutational analysis has an 
important role in the management of GISTs. New therapeutic agents have been developed for 
patients with imatinib resistance.
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